Dusseldorf - Delayed Quote EUR

Arbutus Biopharma Corp (I9DN.DU)

3.1680

-0.0240

(-0.75%)

At close: January 10 at 7:32:07 PM GMT+1

Here’s Why Arbutus (ABUS) Surged in Q3

Tourlite Capital Management, an investment management firm, released its third quarter 2024 investor letter, a copy of which can be downloaded here. Tourlite Fund, LP Founder Class returned 4.5% for Q3 2024 and 13.8% year-t0-date while the S&P 500 Index returned 5.9% and 9.3%, respectively. In addition, please check the fund’s top five holdings to know […]

Insider Monkey last month

ABUS
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

NEW YORK, December 03, 2024--Whitefort Capital Management, LP (together with its affiliates, "Whitefort Capital," "us" or "we"), which is a long-term investor and the third largest shareholder of Arbutus Biopharma Corp. (NASDAQ: ABUS) ("Arbutus" or the "Company") with an ownership interest of approximately 6.8% of the Company’s outstanding shares, today published a letter to the Company’s Board of Directors (the "Board") outlining its views on the actions Arbutus must take in order to preserve a

Business Wire last month

ABUS
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will participate in the virtual H.C Wainwright @ Home fireside chat series taking place on Tuesday, December 3, 2024 at 11:00 am ET. To access the live webcast of t

GlobeNewswire last month

ABUS
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved functional cure Data to be presented in late-breaker poster session at AASLD – The Liver Meeting® on Monday, November 18, 2024 WARMINSTER, Pa., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveragin

GlobeNewswire last month

ABUS
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously 23% of participants receiving imdusiran, VTP-300 and low-dose nivolumab reached HBsAg loss by Week 48 WARMINSTER, Pa. and OXFORD, United Kingdom, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensi

GlobeNewswire last month

ABUS
Arbutus to Present at Jefferies London Healthcare Conference

WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will present at and host one-on-one meetings at the following upcoming investor conference: Jefferies London Healthcare Conference: Fireside Chat on November 21, 20

GlobeNewswire last month

ABUS
Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ...

Arbutus Biopharma Corp (ABUS) showcases significant progress in hepatitis B treatment and maintains a robust cash runway into 2026.

GuruFocus.com 2 months ago

ABUS
Q3 2024 Arbutus Biopharma Corp Earnings Call

Q3 2024 Arbutus Biopharma Corp Earnings Call

Thomson Reuters StreetEvents 2 months ago

ABUS
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 22.82%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

ABUS

SPRO
Arbutus: Q3 Earnings Snapshot

WARMINSTER, Pa. AP) — Arbutus Biopharma Corp. ABUS) on Wednesday reported a loss of $19.7 million in its third quarter.

Associated Press Finance 2 months ago

ABUS
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase 1a/1b clinical trial were generally safe and well-tolerated with evidence of receptor occupancy Now dosing cHBV patients with AB-101 in Part 3 of the Phase 1a/1b clinical trial Cash runway into the fourth quarter of 2026Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Nov. 06, 2024 (G

GlobeNewswire 2 months ago

ABUS
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its third quarter 2024 financial results and corporate update for Wednesday, November 6, 2024. The schedule for the press release and conference call/webcast ar

GlobeNewswire 2 months ago

ABUS
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

WARMINSTER, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that clinical data with imdusiran, an RNAi therapeutic, will be highlighted in four poster presentations at the American Association for the Study of Liver Diseases (AASLD) – The Liv

GlobeNewswire 2 months ago

ABUS
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

WARMINSTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will present at and host one-on-one meetings at the following upcoming investor conference: H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference: Fireside

GlobeNewswire 3 months ago

ABUS
Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year?

Here is how Arbutus Biopharma (ABUS) and Astrazeneca (AZN) have performed compared to their sector so far this year.

Zacks 3 months ago

ABUS

AZN
Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?

Here is how HCA Healthcare (HCA) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Zacks 4 months ago

HCA

ABUS
Arbutus to Participate in Two Upcoming Investor Conferences

WARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York: H.C. Wainwrigh

GlobeNewswire 4 months ago

ABUS
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?

Here is how Arbutus Biopharma (ABUS) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.

Zacks 4 months ago

ABUS
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

Here is how Arbutus Biopharma (ABUS) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.

Zacks 5 months ago

ABUS

ANNX
Q2 2024 Arbutus Biopharma Corp Earnings Call

Q2 2024 Arbutus Biopharma Corp Earnings Call

Thomson Reuters StreetEvents 5 months ago

ABUS

Performance Overview

Return	I9DN.DU	S&P 500
YTD	+6.74%	-1.35%
1-Year	+45.32%	+22.51%
3-Year	+3.12%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Arbutus Biopharma Corp (I9DN.DU)

Here’s Why Arbutus (ABUS) Surged in Q3

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Arbutus to Present at Jefferies London Healthcare Conference

Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ...

Q3 2024 Arbutus Biopharma Corp Earnings Call

Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates

Arbutus: Q3 Earnings Snapshot

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year?

Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?

Arbutus to Participate in Two Upcoming Investor Conferences

Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

Q2 2024 Arbutus Biopharma Corp Earnings Call

Performance Overview